Next Article in Journal
Hypoxia and Chromatin: A Focus on Transcriptional Repression Mechanisms
Next Article in Special Issue
Frontiers in Gastrointestinal Oncology: Advances in Multi-Disciplinary Patient Care
Previous Article in Journal
NF-κB, the Importance of Being Dynamic: Role and Insights in Cancer
Previous Article in Special Issue
Transcriptome Analysis of Acute Phase Liver Graft Injury in Liver Transplantation
Open AccessCase Report

Tumor Molecular Profiling for an Individualized Approach to the Treatment of Hepatocellular Carcinoma: A Patient Case Study

1
Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
2
Department of Radiology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA
3
Department of Pathology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA
4
Division of Hematology-Oncology, Department of Medicine, Penn State Health Milton S. Hershey Medical Center; Experimental Therapeutics Program, Penn State Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
*
Author to whom correspondence should be addressed.
Biomedicines 2018, 6(2), 46; https://doi.org/10.3390/biomedicines6020046
Received: 13 March 2018 / Revised: 7 April 2018 / Accepted: 9 April 2018 / Published: 17 April 2018
(This article belongs to the Special Issue Cancer Biomarkers and Targets in Digestive Organs)
Hepatocellular carcinoma (HCC) is increasing in incidence, and the associated mortality rate remains among the highest. For advanced HCC, sorafenib has been shown to slightly prolong survival, and regorafenib and nivolumab, both recently approved by the United States Food and Drug Administration (FDA), may produce clinical benefits to a limited extent. Systemic chemotherapy has been shown to produce a modest response, but there is no clinically valid biomarker that can be used to predict which patients may benefit. In this case study, we present two patients with metastatic HCC, they received systemic treatment using capecitabine, oxaliplatin, and either bevacizumab or sorafenib. The tumor response to treatment was determined by the progression-free survival (PFS). Molecular profiling of the tumors showed differential expression of biochemical markers and different mutational status of the TP53 and β-catenin (CTNNB1) genes. We hypothesize that the PFS correlates with the tumor molecular profiles, which may be predictive of the therapeutic response to systemic chemotherapy. Further investigation is indicated to correlate tumor biomarkers and treatment responses, with the objective of personalizing the therapies for patients with advanced HCC. View Full-Text
Keywords: hepatocellular carcinoma; immunohistochemistry; molecular profiling; next-generation sequencing; precision medicine; predictive biomarkers hepatocellular carcinoma; immunohistochemistry; molecular profiling; next-generation sequencing; precision medicine; predictive biomarkers
Show Figures

Graphical abstract

MDPI and ACS Style

Posadas, K.; Ankola, A.; Yang, Z.; Yee, N.S. Tumor Molecular Profiling for an Individualized Approach to the Treatment of Hepatocellular Carcinoma: A Patient Case Study. Biomedicines 2018, 6, 46.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop